Cargando…

Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2− advanced breast cancer: a Brazilian public health care system perspective

INTRODUCTION: The MONALEESA-7 trial compared ribociclib plus endocrine therapy (ET) with placebo as first-line treatment of advanced luminal/HER2-negative breast cancer (ABC) in premenopausal and perimenopausal women (age <50 years) and showed significant benefits to progression-free survival and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosa, Daniela Dornelles, Magliano, Carlos Alberto da Silva, Simon, Sergio D., Amorim, Gilberto, Reinert, Tomás, Landeiro, Luciana, Gagliato, Débora de Melo, Exman, Pedro, Argolo, Daniel, Guilgen, Gisah, Mano, Max, Testa, Laura, Liedke, Pedro, Barroso, Romualdo, Sasse, Mariana, Buehler, Anna Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634995/ https://www.ncbi.nlm.nih.gov/pubmed/36339925 http://dx.doi.org/10.1177/17588359221100865

Ejemplares similares

Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women
por: Jeong, Eunae, et al.
Publicado: (2021)

Evidence to date: talazoparib in the treatment of breast cancer
por: Exman, Pedro, et al.
Publicado: (2019)

Genomic Profiling of Premenopausal HR+ and HER2– Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib
por: Bardia, Aditya, et al.
Publicado: (2021)

Cost‐effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore
por: Loke, Lydia, et al.
Publicado: (2020)

Impact of COVID-19 Disease in Early Breast Cancer Management: A Summary of the Current Evidence
por: Cavalcante, Francisco Pimentel, et al.
Publicado: (2022)

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer
por: Tremblay, Gabriel, et al.
Publicado: (2018)

Endometrial evaluation with transvaginal ultrasonography for the screening of endometrial hyperplasia or cancer in premenopausal and perimenopausal women
por: Kim, Min-Jeong, et al.
Publicado: (2016)

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR(+)/HER2(−) Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
por: Lu, Yen-Shen, et al.
Publicado: (2022)

Ovarian cancer risk in premenopausal and perimenopausal women treated with Tamoxifen: a case–control study
por: Swerdlow, A J, et al.
Publicado: (2007)

Ribociclib Improves Overall Survival in HR+/HER2– Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
por: Jacobson, Anne
Publicado: (2022)

A measurement-specific quality-of-life satisfaction during premenopause, perimenopause and postmenopause in Arabian Qatari women
por: Bener, Abdulbari, et al.
Publicado: (2014)

Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program
por: Staropoli, Nicoletta, et al.
Publicado: (2022)

Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil
por: Buehler, Anna Maria, et al.
Publicado: (2022)

Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective
por: Buehler, Anna Maria, et al.
Publicado: (2021)

Sleep Quality and Associated Factors in Premenopausal, Perimenopausal, and Postmenopausal Women in Korea: Findings from the K-Stori 2016
por: Hwang, Ji Hae, et al.
Publicado: (2021)

Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2− metastatic breast cancer: a focus on ribociclib
por: Edessa, Dumessa, et al.
Publicado: (2017)

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2− advanced or metastatic breast cancer in Spain
por: Galve-Calvo, Elena, et al.
Publicado: (2018)

Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer
por: Le, Vivian, et al.
Publicado: (2021)

Ribociclib Induced Photosensitive Skin Lesions
por: Verma, Vaishnavi, et al.
Publicado: (2022)

Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
por: Pribnow, Allison, et al.
Publicado: (2022)

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
por: O’Shaughnessy, Joyce, et al.
Publicado: (2017)

Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy
por: O’Shaughnessy, Joyce
Publicado: (2020)

Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison
por: Rugo, Hope S., et al.
Publicado: (2023)

Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study
por: Oliveira, Leandro Jonata Carvalho, et al.
Publicado: (2022)

Molecular Prognostic Factors for Distant Metastases in Premenopausal Patients with HR+/HER2− Early Breast Cancer
por: Ni, Hua, et al.
Publicado: (2021)

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer
por: Fasching, Peter A, et al.
Publicado: (2021)

Ribociclib-induced Vitiligo: a Case Report
por: Silvestre Torner, Nicolás, et al.
Publicado: (2022)

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant
por: Neven, P., et al.
Publicado: (2023)

Progesterone for Symptomatic Perimenopause Treatment – Progesterone politics, physiology and potential for perimenopause
por: Prior, J.C.
Publicado: (2011)

Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis
por: Berrios, Kevin, et al.
Publicado: (2022)

Perimenopausal and Postmenopausal Health
por: Cheung, Angela M, et al.
Publicado: (2004)

Migraine during perimenopause
por: Battista Allais, Giovanni, et al.
Publicado: (2015)

Don’t ignore perimenopause
por: Prior, Jerilynn C., et al.
Publicado: (2023)

Case Report of Probable DRESS Syndrome Associated with Ribociclib
por: Carneiro, Florian, et al.
Publicado: (2023)

Perimenopausal syndrome and mood disorders in perimenopause: prevalence, severity, relationships, and risk factors
por: Li, Rui-xia, et al.
Publicado: (2016)

Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2− Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study
por: De Laurentiis, Michelino, et al.
Publicado: (2022)

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
por: Slamon, Dennis J., et al.
Publicado: (2023)

The Swiss Perimenopause Study – study protocol of a longitudinal prospective study in perimenopausal women
por: Willi, Jasmine, et al.
Publicado: (2020)

Steroid Hormone Secretion Over the Course of the Perimenopause: Findings From the Swiss Perimenopause Study
por: Grub, Jessica, et al.
Publicado: (2021)

In vitro model of perimenopausal depression implicates steroid metabolic and proinflammatory genes
por: Rudzinskas, Sarah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_li19alpnipqgv0ifaden8rnjud